Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

Bibliographic Details
Main Authors:	Reid, A, Stöhr, W, Walker, A, Williams, I, Kityo, C, Hughes, P, Kambugu, A, Gilks, C, Mugyenyi, P, Munderi, P, Hakim, J, Gibb, D
Format:	Journal article
Language:	English
Published:	2008

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
by: Stöhr, W, et al.
Published: (2011)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.
by: Stöhr, W, et al.
Published: (2008)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
by: Gomo, Z, et al.
Published: (2014)

DART and laboratory monitoring of HIV treatment Reply
by: Walker, A, et al.
Published: (2010)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
by: Gilks, C, et al.
Published: (2013)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
by: Ssali, F, et al.
Published: (2006)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
by: Lara, A, et al.
Published: (2012)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
by: Mugyenyi, P, et al.
Published: (2010)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
by: Muyingo, S, et al.
Published: (2008)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial
by: Kityo, C, et al.
Published: (2014)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
by: Ross, LL, et al.
Published: (2019)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
by: Ford, D, et al.
Published: (2015)

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
by: Paton, N, et al.
Published: (2017)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
by: Ford, D, et al.
Published: (2015)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
by: Kityo, C, et al.
Published: (2010)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
by: Antonieta Medina Lara, et al.
Published: (2012-01-01)

Renal impairment in a rural African antiretroviral programme
by: Lessells Richard J, et al.
Published: (2009-08-01)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
by: Munderi, P, et al.
Published: (2011)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
by: Hakim, J, et al.
Published: (2017)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
by: Lisa L Ross, et al.
Published: (2019-01-01)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
by: Parikh, S, et al.
Published: (2013)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
by: Paton, N, et al.
Published: (2014)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
by: Kikaire, B, et al.
Published: (2007)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
by: Cissy Kityo, et al.
Published: (2014-01-01)

Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status
by: Pett, SL, et al.
Published: (2020)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
by: Kityo, C, et al.
Published: (2018)

Renal Function in Chinese HIV-Positive Individuals following Initiation of Antiretroviral Therapy.
by: Yan Zhao, et al.
Published: (2015-01-01)

Neurocognitive function at the first-line failure and on the second-line antiretroviral therapy in Africa: Analyses from the EARNEST trial.
by: Kambugu, A, et al.
Published: (2016)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
by: Paton, N, et al.
Published: (2014)

Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach
by: Tenforde, M, et al.
Published: (2019)

Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial
by: Thompson, J, et al.
Published: (2018)

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
by: Serwanga, J, et al.
Published: (2011)

Monitoring of highly active antiretroviral therapy in HIV infection.
by: Walker, A, et al.
Published: (2011)

EFFECT OF RENAL DYSFUNCTION ON THE CARDIACVASCULAR SYSTEM. THE POSSIBILI TIES OF EARLY DIAGNOSIS OF THE RENAL DYSFUNCTION
by: B. Zh. Imanov, et al.
Published: (2018-08-01)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

Role of renal dysfunction in development of cirrhosis complications
by: A. S. Tugushev, et al.
Published: (2014-04-01)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.

Similar Items

Similar Items